Bioreversible Derivatization of Peptides

  • Hans Bundgaard
Part of the NATO ASI Series book series (NSSA, volume 125)

Abstract

In recent years several biologically active peptides have been discovered, including peptides consisting of only two or three amino acids, and most certainly, the development of peptide drugs will be a major area in drug research in the future. The application of peptides as clinically useful drugs is, however, seriously hampered due to substantial delivery problems. Peptides are readily degraded by enzymes in the gastrointestinal system and are absorbed poorly, making the oral route a poor way of administration (Wiedhaup, 1981). Pronounced degradation of peptides does also occur at routes of administration other than oral, such as the ocular, nasal, buccal, rectal and vaginal routes (Okada et al., 1982; Kimura, 1984; Lee et al., 1985; Stratford and Lee, 1986). Another factor contributing to the poor bioavailability of peptides is most certainly the non-lipophilicity of peptides. Furthermore, peptides suffer from metabolic lability arising from hydrolysis by plasma and tissue peptidases and even simple parenteric administration is problematic, due to the short half-lives of the peptides once they reach the bloodstream. Several peptides also suffer from systemic transport problems in that they do not readily penetrate cell membranes to reach the receptor biophase or cross the blood-brain barrier (Farmer and Ariëns, 1982; Meisenberg and Simmons, 1983).

Keywords

Mannich Base Peptide Drug Ester Prodrug Tensin Converting Enzyme Inhibitor Lipophilic Prodrug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, J. 1985, (Acyloxyalkoxy)carbony1 derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives, Eur. Pat. Appl., No. 130, 119.Google Scholar
  2. Baker, G.B., Coutts, R.T., Nazarali, A.J., Danielson, T.J., and Rubens, M., 1984, Carbamate prodrugs of phenylethylamines: A neurochemical investigation, Proc. West. Pharmacol. Soc., 27: 523.PubMedGoogle Scholar
  3. Baldwin, J.J., Denny, G. H., Ponticello, G.S., Sweet, C.S. and Stone, C.A., 1982, Tyrosine progenitors as antihypertensive agents, Eur. J. Med. Chem., 17: 297.Google Scholar
  4. Belke, C.J., Su, S.C.K., and Shafer, J.A., 1971, Imidazole-catalyzed displacement of an amine from an amide by a neighboring hydroxyl group. A model for the acylation of chymotrypsin, J. Am. Chem. Soc., 93: 4552.PubMedCrossRefGoogle Scholar
  5. Bodin, N.O., Ekström, B., Forsgren, U., Jalar, L.P., Magni, L. Ramsey, C.H., and Sjöberg B., 1975, Bacampicillin: A new orally well-absorbed derivative of ampicillin, Antimicrob. Agents. Chemother., 8: 518.PubMedCrossRefGoogle Scholar
  6. Bodor, N., Sloan, K.B., Higuchi, T., and Sasahara, K., 1977, Improved delivery through biological membranes. 4. Prodrugs of L-Dopa, J. Med. Chem., 20: 1435.PubMedCrossRefGoogle Scholar
  7. Bodor, N., Zupan, J., and Selk, S., 1980, Improved delivery through biological membranes VII. Dermal delivery of chromoglycic acid (cromolyn) via its prodrugs, Int. J. Pharm., 7: 64.CrossRefGoogle Scholar
  8. Bodor, N., Sloan, K.B., Kminski, J.J., Shih, C., and Pogani, S., 1983, A convenient synthesis of (acyloxy)alkyl α-ethers of phenols, J. Org. Chem., 48: 5280.CrossRefGoogle Scholar
  9. Bundgaard, H., 1976, Polymerization of penicillins: kinetics and mechanisms of di-and polymerization of ampicillin in aqueous solution, Acta Pharm. Suec., 13: 9.PubMedGoogle Scholar
  10. Bundgaard, H., 1982, Novel bioreversible derivatives of amides, imides, ureides, amines and other chemical entities not readily derivatizable, in: “Optimization of drug delivery”, H. Bundgaard, A.B. Hansen and H. Kofod eds., Munksgaard, Copenhagen.Google Scholar
  11. Bundgaard, H., 1985a, Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities, in: “Design of prodrugs”, H. Bundgaard ed., Elsevier Biomedical Press, Amsterdam.Google Scholar
  12. Bundgaard, H., 1985b, The formation of prodrugs of amines, amides, ureides and imides. Methods in Enzymology 112:347.PubMedCrossRefGoogle Scholar
  13. Bundgaard, H. and Johansen, M., 1980a, Pro-drugs as drug delivery systems. IV. N-Mannich bases as potential novel pro-drugs for amides, ureides, amines, and other NH-acidic compounds, J. Pharm. Sci. 69:44.PubMedCrossRefGoogle Scholar
  14. Bundgaard, H. and Johansen, M., 1980b, Pro-drugs as drug delivery systems. X. N-Mannich bases as novel pro-drug candidates for amides, imides, urea derivatives, amines and other NH-acidic compounds. Kinetics and mechanisms of decomposition and structure-reactivity relationships, Arch. Pharm. Chem., Sci. Ed. 8:29.Google Scholar
  15. Bundgaard, H. and Johansen, M., 1980c, Pro-drugs as drug delivery systems. XV. Bioreversible derivatization of phenytoin, acetazolamide, chlorzoxazone and various other NH-acidic compounds by N-aminome-thylation to effect enhanced dissolution rates, Int. J. Pharm. 7:129.CrossRefGoogle Scholar
  16. Bundgaard, H. and Johansen, M. 1981, Hydrolysis of N-Mannich bases and its consequences for the biological testing of such agents, Int. J. Pharm., 9: 7.CrossRefGoogle Scholar
  17. Bundgaard, H. and Johansen, M., 1981, Pro-drugs as drug delivery systems. XVIII. Bioreversible derivatization of allopurinol by N-aminomethylation to effect enhanced dissolution rates, Acta Pharm. Suec., 18: 129.Google Scholar
  18. Bundgaard, H. and Johansen, M., 1982, Prodrugs as drug delivery systems. XIX. Bioreversible derivatization of aromatic amines by formation of N-Mannich bases with succinimide, Int. J. Pharm., 8: 183.CrossRefGoogle Scholar
  19. Bundgaard, H., Klixbüll, U., and Falch, E., 1986, Prodrugs as drug delivery systems. 43. O-Acyloxymethyl salicylamide N-Mannich bases as double prodrug forms for amines, Int. J. Pharm., 29: 19.CrossRefGoogle Scholar
  20. Cain, B.F., 1976, 2-Acyloxymethylbenzoic acids. Novel amine protective functions providing amides with the lability of esters, J. Org. Chem., 41: 2029.CrossRefGoogle Scholar
  21. Caldwell, H.C., Adams, H.J., Jones, R.G., Mann, W.A., Dittert, L.W., Chong, C.W., and Swintosky, J.V., 1971, Enamine prodrugs J. Pharm. Sci., 60: 1810.PubMedCrossRefGoogle Scholar
  22. Cardinaux, F. and Brenner, M., 1973, N, N’-Alkylidenpeptide: Peptidsynthese-Nebenprodukte bei Einwirkung von Carbonylverbindungen, Helv. Chim. Acta, 56: 339.CrossRefGoogle Scholar
  23. Chiong, K.N.G., Lewis, S.D., and Shafer, J.A., 1975, Rationalization of the rate of the acylation step in chymotrypsin-catalyzed hydrolysis of amides, J. Am. Chem. Soc., 97: 418.PubMedCrossRefGoogle Scholar
  24. Clayton, J.P., Cole, M., Elson, S.W., and Ferres, H., 1974, BRL.8988 (talampicillin), a well-absorbed oral form of ampicillin. Antimicrob. Agents Chemother., 5: 670.PubMedCrossRefGoogle Scholar
  25. Daehne, W.v., Frederiksen, E., Gundersen, E., Lund, F., Mørch, P., Petersen, H.J., Roholt, K., Tybring, L., and Godtfredsen, W.O., 1970, acyloxymethyl esters of ampicillin, J. Med. Chem., 13: 607.PubMedCrossRefGoogle Scholar
  26. Digenis, G.A. and Swintosky, J.V., 1975, Drug latentiation, Handbook of Experimental Pharmacology, 28/3:86.Google Scholar
  27. Dixon, K. and Greenhill, J.V., 1974, A study of the rates of hydrolysis of certain enaminones, J. Chem. Soc. Perkin II, 164.Google Scholar
  28. Dobrinska, M.R., Kukovetz, W., Beubler, E., Leidy, H.L., Gomez, H.J., Demetriades, J., and Bolognese, J.A., 1982, Pharmacokinetics of the pivaloyloxyethyl (POE) ester of methyldopa, a new prodrug of methyldopa, J. Pharmacokin. Biopharm., 10: 587.CrossRefGoogle Scholar
  29. Farmer, P.S. and Ariëns, E.J., 1982, Speculations on the design on non-peptidic peptidomimetics, Trends Pharm. Sci., 3: 362.CrossRefGoogle Scholar
  30. Farquhar, D., Srivastva, D.N., Kuttesch, N.J., and Saunders, P.P., 1983, Biologically reversible phosphate-protective groups, J. Pharm. Sci., 72: 324.PubMedCrossRefGoogle Scholar
  31. Fife, T.H. and Benjamin, B.M., 1974, Intramolecular general base-catalyzed alcoholysis of amides, J. Chem. Soc, Chem. Comm. 525.Google Scholar
  32. Ferres, H., 1983, Pro-drugs of ß-lactam antibiotics, Drugs of Today, 19: 499.Google Scholar
  33. Hardcastle, G.A., Johnson, D.A., Panetta, C.A., Scott, A.I., and Sutherland, S.A., 1966, The preparation and structure of hetacillin, J. Org. Chem., 31: 897.PubMedCrossRefGoogle Scholar
  34. Hruby, V.H., Yamashiro, D., Vigneaud, V. du, 1968, The structure of acetone-oxytocin with studies on the reaction of acetone with various peptides. J. Am. Chem. Soc., 90: 7106.PubMedCrossRefGoogle Scholar
  35. Jansen, A.B.A. and Russell, T.J., 1965, Some novel penicillin derivatives, J. Chem. Soc. 2127.Google Scholar
  36. Jemal, M., Ivashkiv, E., Ribick, M., and Cohen, A.I., 1985, Determination of SQ 27,519, The active phosphinic acid-carboxylic acid of the prodrug SQ 28,555, in human serum by capillary gas chromatography with nitrogen-phosphorus detection after a two-step derivatization, J.Chromatogr., 345: 299.PubMedGoogle Scholar
  37. Jusko, W.J. and Lewis, G.P., 1973, Comparison of ampicillin and hetacillin pharmacokinetics in man, J. Pharm. Sci., 62: 69.PubMedCrossRefGoogle Scholar
  38. Johansen, M. and Bundgaard, H., 1980a, Pro-drugs as drug delivery system. XII. Solubility, dissolution and partitioning behaviour of N-Mannich bases and N-hydroxymethyl derivatives, Arch. Pharm. Chem., Sci. Ed. 8:141.Google Scholar
  39. Johansen, M. and Bundgaard, H., 1980b, Pro-drugs as drug delivery systems. XIII. Kinetics of decomposition of N-Mannich bases of salicylamide and assessment of their suitability as possible pro-drugs for amines, Int. J. Pharm. 7:119.CrossRefGoogle Scholar
  40. Johansen, M. and Bundgaard, H., 1982, Pro-drugs as drug delivery systems. XXIV. N-Mannich bases as bioreversible lipophilic transport forms of ephedrine, phenethylamine and other amines, Arch. Pharm. Chem., Sci. Ed., 10: 111.Google Scholar
  41. Kakeya, N., Nishimura, K.-I., Yoshimi, A., Nakamura, S., Nishizawa, S., Tamaki, S., Matsui, H., Kawamura, T., Kasai, M., and Kitae, K., 1984, Studies of prodrugs of cephalosporins. I. Synthesis of biological properties of glycyloxybenzoyloxymethyl and glycylaminobenzoyloxy-methyl esters of 7 ß-[2-(2-aminothiazol-4-yl)-(Z)-2-methoxyimino-acetamido]-3-methyl-3-cephem-4-carboxylic acid, Chem. Pharm. Bull., 32: 692.PubMedCrossRefGoogle Scholar
  42. Kimura, T., 1984, Transmucosal absorption of small peptide drugs, Pharm. Int., 5: 75.Google Scholar
  43. Klixbüll, U. and Bundgaard, H., 1983, Prodrugs as drug delivery systems. XXIX. Imidazole-1-carboxylic acid esters of hydrocortisone and testosterone, Arch. Pharm. Chem., Sci. Ed., 11: 101.Google Scholar
  44. Klixbüll, U. and Bundgaard, H., Prodrugs as drug delivery systems. XXX. 4-Imidazolidinones as potential bioreversible derivatives for the α-aminoamide moiety in peptides, Int. J. Pharm. 20:273.Google Scholar
  45. Klixbüll, U. and Bundgaard, H., 1985, Kinetics of reversible reactions of ampicillin with various aldehydes and ketones with formation of 4-Imidazolidinones, Int. J. Pharm., 23: 163.CrossRefGoogle Scholar
  46. Kupchan, S.M. and Isenberg, A.C., 1967, Drug latentiation. III. Labile amide derivatives of normeperidine, J. Med. Chem., 10: 960.PubMedCrossRefGoogle Scholar
  47. Kyncl, J.J., Minard, F.N., and Jones, P.H., 1979, L-α-Glutamyl dopamine, an oral dopamine prodrug with renal selectivity, Adv. Biosci., 20: 369.Google Scholar
  48. Larmour, I., Jackson, B., Cubela, R. and Johnston, C.I., 1985, Enalapril (MK421) activation in man: importance of liver status, Br. J. Clin. Pharmacol., 19: 701.PubMedCrossRefGoogle Scholar
  49. Larsen, J.D. and Bundgaard, H., 1986, Prodrugs as drug delivery systems. 49. Hydrolysis kinetics of enaminones derived from various amino acids and 1,3-diketones, keto-esters and keto-amides, Arch. Pharm. Chem., Sci. Ed., 14: 52.Google Scholar
  50. Lee, V.H.L., Stratfors, R.E., Carson, L.W., and Kashi, S.D., 1985, Effect of ocular aminopeptidases on ocular absorption of enkephalins, Invest. Ophthalmol. Vis. Sci. Suppl., 26: 106.Google Scholar
  51. Loftsson, T. and Bodor, N., 1982, Synthesis and hydrolysis of some pivaloyloxymethyl and pivaloyl derivatives of phenolic compounds, Arch. Pharm. Chem., Sci. Ed., 10: 104.Google Scholar
  52. Meisenberg, G. and Simmons, W.H., 1983, Peptides and the blood-brain barrier, Life Sci., 32: 2611.PubMedCrossRefGoogle Scholar
  53. Murakami, T., Tamauchi, H., Yamazaki, M., Kubo, K., Kamada, A., and Yata, N., 1981, Biopharmaceutical study on the oral and rectal administrations of enamine prodrugs of amino acid-like ß-lactam antibiotics in rabbits, Chem. Pharm. Bull., 29: 1986.PubMedCrossRefGoogle Scholar
  54. Murakami, T., Yata, N., Tamauchi. H., Nakai, J., Yamazaki, M., and Kamada, A., 1981, Studies on absorption promotors for rectal delivery preparations. I. Promoting efficacy of enamine derivatives of amino acids for the rectal absorption of ß-lactam antibiotics in rabbits, Chem. Pharm. Bull., 29: 1998.PubMedCrossRefGoogle Scholar
  55. Nielsen, N.M., and Bundgaard, H., 1986, Prodrugs as drug delivery systems. Part. 42. 2-Hydroxymethylbenzamides and 2-acyloxymethyl-benzamides as potential prodrug forms for amines, Int. J. Pharm., 29: 9.CrossRefGoogle Scholar
  56. Okada, H., Yamazaki, I., Ogawa, Y., Hirai, S., Yoshiki, T., and Mima, H.J., 1982, Vaginal absorption of a potent luteinizing hormone-releasing hormone analog (Leuprolide) in rats I: Absorption by various routes and absorption enhancement, J. Pharm. Sci., 71: 1367.PubMedCrossRefGoogle Scholar
  57. Okuyama, T. and Schmir, G.L., 1972, Hydrolysis of 1-benzylimino-1,3-dihydroisobenzofuran. Implications for the mechanism of lactonization of 2-hydroxymethylbenzamides, J. Am. Chem. Soc. 94:8805.CrossRefGoogle Scholar
  58. Orlowski, M., Mizoguchi, H., and Wilk, S., 1979, N-Acyl-y-glutamyl derivatives of sulfamethoxazole as models of kidney-selective prodrugs, J. Pharmacol. Exp. Ther., 212: 167.Google Scholar
  59. Pitman, I.H., 1981, Prodrugs of amides, imides and amines, Med. Res. Rev., 1: 189.PubMedCrossRefGoogle Scholar
  60. Rakhit, A. and Tipnis, V., 1984, Liquid-chromatographic determination of an angiotensin converting enzyme inhibitor, CGS 13945, and its active metabolite (CGS 13934) in plasma, Clin. Chem., 30: 1237.PubMedGoogle Scholar
  61. Roche, E.B., ed., 1977, “Design of biopharmaceutical properties through prodrugs and analogs”, Washington, D.C., American Pharmaceutical Association.Google Scholar
  62. Saari, W.S., Freedman, M.B., Hartman, R.D., King, S.W., Raab, A.W., Randall, W.C., Engelhardt, E.L., Hirschman, R., Rosegay, A., Ludden, C.T., and Scriabine, A., 1978, Synthesis and antihypertensive activity of some ester progenitors of methyldopa, J. Med. Chem., 21: 746.PubMedCrossRefGoogle Scholar
  63. Saari, W.S., Halczenko, W., Cochran, D.W., Dobrinska, M.R., Vincek, W.C., Titus, D.C., Gaul, S.L., and Sweet, C.S., 1984, 3-Hydroxy-α-methyltyrosine progenitors: Synthesis and evaluation of some (2-oxo-1,3-dioxol-4-yl)methylesters, J. Med. Chem., 27: 713.PubMedCrossRefGoogle Scholar
  64. Sakamoto, F., Ikeda, S., and Tsukamoto, G., 1984, Studies on prodrugs. II. Preparation and characterization of (5-substituted 2-oxo-1,3-dioxolen-4-yl)methyl esters of ampicillin, Chem. Pharm. Bull., 32: 2241.PubMedCrossRefGoogle Scholar
  65. Sakamoto, F., Ikeda, S., Kondo, H., and Tsukamoto, G., 1985, Studies on prodrugs. IV. Preparation and characterization of N-(5-substituted 2-oxo-1,3-dioxol-4-yl)methyl norfloxacin, Chem. Pharm. Bull., 33: 4870.PubMedCrossRefGoogle Scholar
  66. Sasaki, H., Mukai, E., Hashida, M., Kimura, T., and Sezaki, H., 1983, Development of lipophilic prodrugs of mitomycin C. I. Synthesis and antitumor activity of 1a-N-substituted derivatives with aromatic pro-moiety, Int. J. Pharm., 15: 49.CrossRefGoogle Scholar
  67. Sasaki, H., Mukai, E., Hashida, M., Kimura, T., and Sezaki, H., 1983, Development of lipophilic prodrugs of mitomycin C. II. Stability and bioactivation of 1a-N-substituted derivatives with aromatic pro-moiety, Int. J. Pharm., 15: 61.CrossRefGoogle Scholar
  68. Sasaki, H., Fukumoto, M. Hashida, M., Kimura, T., and Sezaki, H., 1983, Development of lipophilic prodrugs of mitomycin C. III. Physicochemical and biological properties of newly synthesized alkoxycarbonyl derivatives, Chem. Pharm. Bull., 31: 4083.PubMedCrossRefGoogle Scholar
  69. Schwartz, M.A. and Hayton, W.L., 1972, Relative stability of hetacillin and ampicillin in solution, J. Pharm. Sci., 61: 906.PubMedCrossRefGoogle Scholar
  70. Shiobara, Y., Tachibana, A., Sasaki, H., Watanabe, T., and Sado, T., 1974, Phthalidyl D-α-aminobenzylpenicillinate hydrochloride (PC-183), a new orally active ampicillin ester. J. Antibiot., 27: 665.PubMedCrossRefGoogle Scholar
  71. Sinkula, A.A., 1975, Prodrug approach in drug design, Annual Reports in Medicinal Chemistry, 10: 306.CrossRefGoogle Scholar
  72. Sinkula, A.A. and Yalkowsky, S.H., 1975, Rationale for design of biologically reversible drug derivatives: Prodrugs, J. Pharm. Sci. 64:181.PubMedCrossRefGoogle Scholar
  73. Srivastva, D.N. and Farquhar, D., 1984, Bioreversible phosphate protective groups: Synthesis and stability of model acyloxymethyl phosphates, Bioorg. Chem., 12: 118.CrossRefGoogle Scholar
  74. Stella, V., 1975, Pro-drugs: An overview and definition, in: “Pro-drugs as novel drug delivery systems”, T. Higuchi and V. Stella, eds./ American Chemical Society, Washington, D.C.Google Scholar
  75. Stratford, R.E. and Lee, V.H.L., 1986, Aminopeptidase activity in homogenates of various absorptive mucosae in the albino rabbit: implications in peptide delivery, Int. J. Pharm., 30: 73.CrossRefGoogle Scholar
  76. Summers, M.C., Gidley, M.J., and Sanders, J.K., 1980, “Acetaldehyde-enkephalins”: elucidation of the structure of the acetaldehyde adducts of methionine-enkephalin and leucine-enkephalin, FEBS Lett., 111: 307.PubMedCrossRefGoogle Scholar
  77. Summers, M.C. and Lightman, S.L., 1981, A reaction of acetaldehyde with enkephalins and related peptides, Biochem. Pharmacol., 30: 1621.PubMedCrossRefGoogle Scholar
  78. Tipnis, V. and Rakhit, A., 1985, Determination of pentopril, an angiotensin converting enzyme inhibitor, and its active metabolite in urine, J. Chromatogr., 345: 396.PubMedGoogle Scholar
  79. Todd, P.A. and Heel, R.C., 1986, Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure, Drugs, 31: 198.PubMedCrossRefGoogle Scholar
  80. Verbiscar, A.J. and Abood, L.G., 1970, Carbamate ester latentiation of physiologically active amines, J. Med. Chem., 13: 176.Google Scholar
  81. Vickers, S., Duncan, C.A.H., Ramjit, H.G., Dobrinska, M.R., Dollery, C.T., Gomez, H.J., Leidy, H.L., and Vincek, W.C., 1984, Metabolism of methyldopa in man after oral administration of the pivaloyloxyethyl ester, Drug Metab. Disp., 12: 242.Google Scholar
  82. Wiedhaup, K., 1981, The stability of small peptides in the gastrointestinal tract, in: “Topics in Pharmaceutical Sciences”, D.D. Breimer and P. Speiser, eds., Elsevier/North-Holland Biomedical Press, Amsterdam.Google Scholar
  83. Wilk, S., Mizoguchi, H., and Orlowski, M., 1978, γ-Glutamyl Dopa: A kidney-specific dopamine precursor, J. Pharmacol. Exp. Ther., 206: 227.PubMedGoogle Scholar
  84. Yamashiro, D., Aanning, H.L., and Vigneaud, V. du, 1965, Inactivation of oxytocin by acetone, Proc. Natl. Acad. Sci. U.S.A., 54: 166.PubMedCrossRefGoogle Scholar
  85. Zlojkowska, Z., Krasuka, H.J., and Pachecka, J., 1982/ Enzymatic hydrolysis of amino acid derivatives of benzocaine, Xenobiotica 12:359.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1986

Authors and Affiliations

  • Hans Bundgaard
    • 1
  1. 1.Department of Pharmaceutical Chemistry ADRoyal Danish School of PharmacyCopenhagenDenmark

Personalised recommendations